Animal Model Market Size, Share & Trends Analysis Report By Animal Type (Mice, Guinea Pigs), By Application (Cancer, Infectious Disease), By End-use (CRO, Academic Research Institute), By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global animal model market size was estimated at USD 2.10 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 8.6% from 2023 to 2030. The increasing use of animal models in biomedical research, neurological research, genetic research, toxicology, and cancer research is driving global market growth. Moreover, growing R&D efforts by biopharmaceutical companies to develop novel therapeutics and the emergence of advanced technologies, such as CRISPR, in the field of biomedical research are other factors contributing to industry expansion. The rising R&D efforts to develop novel therapeutics, along with supportive government legislation for various animal-based models are projected to support global industry growth.

For instance, in October 2020, the National Institutes of Health funded USD 9.3 million for the Center For Precision Animal Modeling at the University of Alabama. This funding aimed at strengthening precision disease modeling. Similarly, in April 2022 MRC launched a National Mouse Genetics Network to tackle major challenges in areas of unmet clinical needs. Technological advancements in genome editing and genetic engineering technologies have brought a revolution in the field of animal modeling. The capability to alter genes in animals allows scientists to create models that largely mimic human diseases, leading to more precise and accurate results.

These technological advancements have exponentially leveraged the utility of animal models, thereby supporting market growth. For instance, in May 2023, researchers from the Massachusetts Institute of Technology developed an innovative way to engineer specific cancer-linked mutations into mouse models and utilized the CRISPR technique to make models of various mutations. Moreover, advancements in biomedical research, and rising efforts from industry participants to develop more precise animal models to mimic exact human conditions are accelerating industry expansion. In addition, advances in genetic engineering and ongoing research efforts to develop new models are further supporting market growth.

For instance, in January 2023, BioMed X and AbbVie extended their research collaboration to focus more on immunology and tissue engineering. In addition, this partnership is emphasized developing a novel tissue engineering platform to make complex human ex vivo models. Whereas stringent rules and regulations pertaining to various animal-based testing and the development of various alternatives for animal-based testing are projected to hamper industry growth. For instance, acts and authorities like the Animal Welfare Act, USDA, Association for Assessment and Accreditation of Laboratory Animal Care, and others are involved in preventing animal cruelty. Thus, such regulations pose a threat to the global market.

Animal Type Insights

The mice segment accounted for the largest revenue share of 52.7% in 2022 and is expected to witness the fastest growth rate from 2023 to 2030. Factors, such as increasing investments and technological advancement in mouse model technology are anticipated to drive segment growth. In addition, rising implications of mouse clinical trials for more predictive outcomes, and propelling demand for personalized medicine are further contributing to the demand for mice models. For instance, on March 2023, researchers from the National Institutes of Health studied an enhanced genetic animal model of Down syndrome. The novel mouse model delivered potential therapeutic options for managing the condition.

These may help scientists to develop advanced therapeutic approaches for Down syndrome. Furthermore, the presence of established research infrastructure and the availability of genetically modified mice are projected to propel segment growth forward. The guinea pigs segment accounted for the second-largest revenue sharein 2022 and is likely to hold a significant share in the coming years. Factors, such as wide regulatory acceptance, well-characterized strains of guinea pig, and lack of alternative methods are projected to fuel segment expansion. Also, the unique physiologic characteristics of guinea pigs make them suitable for numerous research areas.

Application Insights

The cancer segment dominated the application segment in 2022 with a market share of 43.0% and it is expected to register the fastest growth rate over the forecast period. Factors, such as the translational relevance of animal models in cancer research, the rising trend of precision oncology, and advancements in tumor modeling techniques are projected to fuel the segment growth. These models are exponentially used in drug screening and preclinical testing to evaluate the efficacy and safety of anti-cancer therapeutics. Also, animal models help researchers in evaluating the therapeutic index, bioavailability, and pharmacokinetic properties of anti-cancer therapeutics before moving to human clinical trials.

Some of the companies offering models for cancer research and therapeutic development are Charles River Laboratories and Creative Biolabs among others. The high burden of immunological disorders and increasing efforts by biopharmaceutical companies to develop therapeutics for various immunologic disorders are fueling the growth of the immunological disease segment. Animal models offer a crucial way to evaluate disease mechanisms, immunological processes and also help investigate various treatment approaches for the condition.

End-use Insights

The pharmaceutical & biotechnology companies segment captured the largest market share of 39.1% in 2022. Increasing efforts by companies to develop novel treatment regimens are projected to drive the segment’s growth. Also, growth in drug discovery & development activities by pharmaceutical companies is further contributing to segment expansion. In addition, large numbers of research-driven pharmaceutical companies and various initiatives undertaken by them are projected to fuel segment growth.

On the contrary, the contract research organization segment is projected to register the fastest growth rate during the forecast years. The preference for outsourcing activities due to time and cost constraints, and increasing investment in R&D programs, are key factors anticipated to drive market growth in the coming years. Contract research outsourcing collaborations provide cutting-edge services and thus government organizations prefer giving projects to contract research organizations, thereby augmenting the industry expansion.

Regional Insights

North America dominated the global market with a share of 48.95% in 2022 and the region is anticipated to register a steady growth rate during the forecast period. The region’s growth is attributed to the presence of key players and various strategic initiatives undertaken by them. In addition, the growing biomedical research and rising investment in clinical trials are contributing to regional market growth. Furthermore, advancements in genetic engineering and the rising adoption of animal-based models to study drug profiling and characterization are likely to bring newer avenues for market growth.

Asia Pacific is likely to register the fastest growth rate from 2023 to 2030. The high disease burden of chronic diseases, such as cancer, immunological disorders, and rare genetic disorders, is projected to support the growth of the regional market. Moreover, significant investments made by key industry participants in the region, coupled with supportive government legislation for research, is another factor fueling the growth of the regional market.

Key Companies & Market Share Insights

Key players in the market are undertaking various strategic initiatives to maintain their market presence. In addition, various strategic initiatives help players in bolstering their business avenues. For instance, in May 2023, a group of scientists from University Hospital Carl Gustav Carus developed a humanized mouse with a defective gene causing congenital adrenal hyperplasia. This achievement is likely to be a breakthrough in cracking the disease and bringing novel therapeutics for its treatment. Some of the key players in the global animal model market include:

• Charles River Laboratories

• The Jackson Laboratory

• genOway

• Taconic Biosciences, Inc.

• Janvier Labs

• Harbour BioMed

• Crown Bioscience

• Inotiv

• BIOCYTOGEN

• BioSpherix, Ltd.

Animal Model Market Report Scope

Global Animal Model Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the animal model market report on the basis of animal type, application, end-use, and region:

• Application Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • Cancer

  • Immunological Disease

  • Infectious Disease

  • Others

• Animal Type Scope Outlook (Revenue, USD Million, 2018 - 2030)

  • Mice

  • Rat

  • Guinea Pigs

  • Rabbits

  • Hamsters

  • Others

• End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Pharmaceutical & Biotechnology Companies

  • Academic Research Institute

  • Contract Research Organization

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • India

    • Japan

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait